2015 Q3 Form 10-Q Financial Statement
#000143774915020830 Filed on November 16, 2015
Income Statement
| Concept | 2015 Q3 | 2014 Q3 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | -100.0% | |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $430.0K | $330.0K |
| YoY Change | 30.3% | 371.43% |
| % of Gross Profit | ||
| Research & Development | $341.0K | $789.0K |
| YoY Change | -56.78% | |
| % of Gross Profit | ||
| Depreciation & Amortization | ||
| YoY Change | ||
| % of Gross Profit | ||
| Operating Expenses | $341.0K | $789.0K |
| YoY Change | -56.78% | 1027.14% |
| Operating Profit | -$770.0K | -$1.114M |
| YoY Change | -30.88% | 2128.0% |
| Interest Expense | $38.00K | $41.00K |
| YoY Change | -7.32% | |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$46.00K | -$34.00K |
| YoY Change | 35.29% | |
| Pretax Income | -$816.0K | -$1.148M |
| YoY Change | -28.92% | 1813.33% |
| Income Tax | -$23.00K | -$4.000K |
| % Of Pretax Income | ||
| Net Earnings | -$793.0K | -$1.144M |
| YoY Change | -30.68% | 1806.67% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$580.9K | -$2.192M |
| COMMON SHARES | ||
| Basic Shares Outstanding | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2015 Q3 | 2014 Q3 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $1.790M | $130.0K |
| YoY Change | 1276.92% | 30.0% |
| Cash & Equivalents | $1.786M | $2.926M |
| Short-Term Investments | $0.00 | |
| Other Short-Term Assets | $50.00K | $0.00 |
| YoY Change | ||
| Inventory | ||
| Prepaid Expenses | $49.00K | |
| Receivables | $150.0K | |
| Other Receivables | $0.00 | |
| Total Short-Term Assets | $1.958M | $280.0K |
| YoY Change | 599.29% | -30.0% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $20.00K | |
| YoY Change | 100.0% | |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $83.00K | $0.00 |
| YoY Change | ||
| Total Long-Term Assets | $83.00K | $20.00K |
| YoY Change | 315.0% | -84.62% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $1.958M | $280.0K |
| Total Long-Term Assets | $83.00K | $20.00K |
| Total Assets | $2.041M | $300.0K |
| YoY Change | 580.33% | -43.4% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $638.0K | $0.00 |
| YoY Change | -100.0% | |
| Accrued Expenses | $31.00K | $60.00K |
| YoY Change | -48.33% | 200.0% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $250.0K | $570.0K |
| YoY Change | -56.14% | 0.0% |
| Long-Term Debt Due | $10.00K | |
| YoY Change | 0.0% | |
| Total Short-Term Liabilities | $919.0K | $670.0K |
| YoY Change | 37.16% | 3.08% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $300.0K | $0.00 |
| YoY Change | -100.0% | |
| Other Long-Term Liabilities | $40.00K | |
| YoY Change | ||
| Total Long-Term Liabilities | $3.111M | $0.00 |
| YoY Change | -100.0% | |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $919.0K | $670.0K |
| Total Long-Term Liabilities | $3.111M | $0.00 |
| Total Liabilities | $4.030M | $670.0K |
| YoY Change | 501.49% | 1.52% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$12.94M | |
| YoY Change | ||
| Common Stock | $30.00K | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | -$1.989M | -$380.0K |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $2.041M | $300.0K |
| YoY Change | 580.33% | -43.4% |
Cashflow Statement
| Concept | 2015 Q3 | 2014 Q3 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$793.0K | -$1.144M |
| YoY Change | -30.68% | 1806.67% |
| Depreciation, Depletion And Amortization | ||
| YoY Change | ||
| Cash From Operating Activities | -$880.0K | -$2.210M |
| YoY Change | -60.18% | 22000.0% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | ||
| YoY Change | ||
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $500.0K | -$40.00K |
| YoY Change | -1350.0% | -166.67% |
| Cash From Investing Activities | $500.0K | -$40.00K |
| YoY Change | -1350.0% | -166.67% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 1.170M | 2.410M |
| YoY Change | -51.45% | -24200.0% |
| NET CHANGE | ||
| Cash From Operating Activities | -880.0K | -2.210M |
| Cash From Investing Activities | 500.0K | -40.00K |
| Cash From Financing Activities | 1.170M | 2.410M |
| Net Change In Cash | 790.0K | 160.0K |
| YoY Change | 393.75% | 300.0% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$880.0K | -$2.210M |
| Capital Expenditures | ||
| Free Cash Flow | ||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2015 | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2015-09-30 | ||
| snbp |
Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
|
375000 | ||
| CY2015Q3 | snbp |
Capital Stock Shares Authorized
CapitalStockSharesAuthorized
|
110000000 | |
| CY2015Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
29892806 | |
| CY2014Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
5688927 | |
| CY2015Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
29892806 | |
| CY2014Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
5688927 | |
| CY2015Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
638000 | |
| CY2014Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
335000 | |
| snbp |
Increase Decrease In Income And Other Taxes Receivable
IncreaseDecreaseInIncomeAndOtherTaxesReceivable
|
2000 | ||
| snbp |
Increase Decrease In Income And Other Taxes Receivable
IncreaseDecreaseInIncomeAndOtherTaxesReceivable
|
-85000 | ||
| CY2015Q3 | snbp |
Merger Agreement Ownership Percentage By Former Shareholders
MergerAgreementOwnershipPercentageByFormerShareholders
|
0.988 | |
| CY2015Q3 | snbp |
Merger Number Of Shares Called By Rights
MergerNumberOfSharesCalledByRights
|
28442484 | |
| CY2015Q3 | snbp |
Merger Number Of Shares For Every Cancelled Share
MergerNumberOfSharesForEveryCancelledShare
|
4 | |
| snbp |
Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
|
|||
| CY2015Q3 | snbp |
Working Capital
WorkingCapital
|
1000000 | |
| CY2015Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
31000 | |
| CY2014Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
132000 | |
| CY2015Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-23000 | |
| CY2014Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-17000 | |
| CY2015Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
10943000 | |
| CY2014Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
7264000 | |
| us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
933000 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
9000 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
100000 | ||
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
21000 | ||
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
20000 | ||
| CY2015Q3 | us-gaap |
Assets
Assets
|
2041000 | |
| CY2014Q4 | us-gaap |
Assets
Assets
|
2478000 | |
| CY2015Q3 | us-gaap |
Assets Current
AssetsCurrent
|
1958000 | |
| CY2014Q4 | us-gaap |
Assets Current
AssetsCurrent
|
2373000 | |
| CY2015Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1786000 | |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1653000 | |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2693000 | |
| CY2014Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2926000 | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
133000 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
233000 | ||
| CY2015Q3 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
2550000 | |
| CY2015Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2014Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2015Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2014Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2015Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2014Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
20000000 | |
| CY2015Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
30000 | |
| CY2014Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
6000 | |
| CY2015Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-785000 | |
| CY2014Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-1157000 | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-4205000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-2557000 | ||
| CY2015Q3 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
2775000 | |
| CY2014Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
3000000 | |
| us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
226000 | ||
| us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
|||
| CY2015Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.06 | |
| CY2014Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.22 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.49 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.50 | ||
| us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
|
-23000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
|
-4000 | ||
| CY2015Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
429000 | |
| CY2014Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
325000 | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2224000 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
838000 | ||
| CY2015Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-816000 | |
| CY2014Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-1148000 | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-4317000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-118000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-63000 | ||
| CY2015Q3 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
123000 | |
| CY2014Q4 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
108000 | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
208000 | ||
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-40000 | ||
| us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
31000 | ||
| CY2014Q3 | us-gaap |
Interest Expense
InterestExpense
|
41000 | |
| us-gaap |
Interest Expense
InterestExpense
|
117000 | ||
| us-gaap |
Interest Expense
InterestExpense
|
115000 | ||
| us-gaap |
Interest Paid
InterestPaid
|
87000 | ||
| us-gaap |
Interest Paid
InterestPaid
|
34000 | ||
| us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-20000 | ||
| CY2015Q3 | us-gaap |
Interest Expense
InterestExpense
|
38000 | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-2618000 | ||
| CY2015Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-23000 | |
| CY2014Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-4000 | |
| CY2015Q3 | us-gaap |
Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
|
36000 | |
| CY2014Q4 | us-gaap |
Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
|
27000 | |
| CY2015Q3 | us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
||
| CY2014Q3 | us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
2000 | |
| us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
5000 | ||
| us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
9000 | ||
| us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
42000 | ||
| us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
91000 | ||
| CY2015Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
2041000 | |
| CY2014Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
2478000 | |
| CY2015Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
919000 | |
| CY2014Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
467000 | |
| CY2015Q3 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
3111000 | |
| CY2014Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
3327000 | |
| CY2015Q3 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
300000 | |
| CY2014Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
300000 | |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 5%; VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2.</div></div></div></td> <td style="WIDTH: 95%; VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; font-weight: bold;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risks and Uncertainties</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration (“TGA”) in Australia, the European Medicines Agency (“EMA”) in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may take many years, and is normally expected to involve substantial expenditures.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have incurred losses of $13.0 million since Sun BioPharma Delaware’s inception in 2011. For the nine months ended September 30, 2015, we incurred a net loss and negative cash flows from operating activities of $4.2 million and $3.0 million, respectively. We expect to incur substantial losses for the foreseeable future, which will continue to generate negative net cash flows from operating activities, as we continue to pursue research and development activities and seek to commercialize our primary product candidate, SBP-101</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">. As of September 30, 2015, we had cash and cash equivalents of $1.8 million, working capital of $1.0 million and shareholders’ deficit of $2.0 million. We believe our cash and cash equivalents as of September 30, 2015, will be sufficient to fund our planned operations through the first quarter of 2016. The Company’s principal sources of cash have included the issuance of convertible debt and equity securities. </div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business and do not include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. SBR’s independent registered public accounting firm, which is also our current independent registered public accounting firm, included a paragraph emphasizing this going concern uncertainty in their audit report on SBR’s 2014 financial statements dated April 16, 2015 (the “2014 Audit Report”) and filed as Exhibit 99.1 to our current report on Form 8-K filed September 11, 2015. Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-101 product candidate in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our SBP-101 product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern. See note 4 entitled “Liquidity and Management’s Plans.”</div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">These factors, among others, raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements included herein do not include any adjustments relating to the recoverability or classification of asset carry amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.</div></div></div> | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
2675000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
2411000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
500000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
|||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-3019000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-2174000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-13000000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-4199000 | ||
| CY2015Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-793000 | |
| CY2014Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1144000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-2555000 | ||
| CY2015Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-46000 | |
| CY2014Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-34000 | |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-157000 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-88000 | ||
| us-gaap |
Notes Assumed1
NotesAssumed1
|
250000 | ||
| us-gaap |
Notes Assumed1
NotesAssumed1
|
|||
| CY2015Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-770000 | |
| CY2014Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1114000 | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4160000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2530000 | ||
| CY2015Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
83000 | |
| CY2014Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
105000 | |
| CY2015Q3 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
8000 | |
| CY2014Q3 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-13000 | |
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-6000 | ||
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-2000 | ||
| CY2015Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-8000 | |
| CY2014Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
5000 | |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-45000 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
18000 | ||
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
-12000 | ||
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
|||
| CY2015Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2014Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2015Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2015Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2015Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2015Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2014Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2015Q3 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
49000 | |
| CY2014Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
18000 | |
| CY2014Q1 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
100000 | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1513000 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
|||
| us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
|||
| us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
2400000 | ||
| us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
500000 | ||
| us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
|||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
762000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
11000 | ||
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
400000 | ||
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
|||
| CY2015Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
341000 | |
| CY2014Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
5186268 | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
8532816 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
5108656 | ||
| CY2014Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
789000 | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1936000 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1692000 | ||
| CY2015Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-12939000 | |
| CY2014Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-8569000 | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
933000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
105000 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
|||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
|||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
3193616 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
5340000 | ||
| CY2015Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5043600 | |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5487752 | |
| CY2015Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5043600 | |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
0.24 | |
| CY2015Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
0.28 | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0.20 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
0.28 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0.32 | ||
| CY2015Q3 | us-gaap |
Share Price
SharePrice
|
1.27 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y | ||
| CY2015Q3 | us-gaap |
Short Term Borrowings
ShortTermBorrowings
|
250000 | |
| CY2014Q4 | us-gaap |
Short Term Borrowings
ShortTermBorrowings
|
||
| CY2015Q3 | us-gaap |
Short Term Investments
ShortTermInvestments
|
||
| CY2014Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
499000 | |
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
2590536 | ||
| us-gaap |
Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
|
-250000 | ||
| us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
226000 | ||
| us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
42000 | ||
| us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
1513000 | ||
| us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
693000 | ||
| CY2015Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-1989000 | |
| CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-1316000 | |
| CY2015Q3 | us-gaap |
Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
|
||
| CY2014Q4 | us-gaap |
Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
|
94000 | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 9pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of estimates</div></div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div></div> | ||
| CY2015Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
13574929 |
